Formerly operating as an independent company after 12 years as a wholly owned subsidiary of Novo Nordisk A/S, in September 2010, ZymoGenetics Inc was acquired by Bristol-Myers Squibb. ZymoGenetics Inc. is focused on the discovery, development and commercialization of therapeutic proteins for the treatment of human disease. The Company has been longtime active in the area of therapeutic proteins having contributed to the discovery or development of many marketed recombinant protein products. These products include recombinant versions of proteins previously made from human or animal sources (Novolin (insulin) and GlucaGen (glucagon), marketed by Novo Nordisk) and novel proteins that come from its discoveries (NovoSeven (Factor VIIa), marketed by Novo Nordisk, as well as Regranex (platelet-derived growth factor), marketed by Ortho-McNeil Pharmaceuticals, Inc., a Johnson & Johnson company, and Cleactor (tPA analog), marketed by Eisai Co., Ltd).
